title: Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
authors.forename: Katherine R
authors.initials: KR
authors.lastname: Tuttle
authors.forename: Cory
authors.initials: C
authors.lastname: Heilmann
authors.forename: Byron J
authors.initials: BJ
authors.lastname: Hoogwerf
authors.forename: Carl
authors.initials: C
authors.lastname: Brown
authors.forename: Pamela W
authors.initials: PW
authors.lastname: Anderson
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000503:physiopathology*; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D014688:Venoms / Q000009:adverse effects*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide